Mounjaro Malta: What to Know Before Starting

Last reviewed by the Carisma Medical Team — 2026

Grace had spent two months reading everything she could find about Mounjaro before she finally opened a browser tab to book a consultation in Malta. She is 47, a senior operations manager, and she has watched her body change in ways that feel completely disconnected from anything she is actually doing wrong. The same portions, the same walks she has always taken, and yet the weight keeps settling around her middle in a way it never did before. She had heard about Mounjaro through a colleague. She was excited but cautious — she wanted to understand exactly what she was agreeing to before the first injection, not after. She came in with a list of questions. That preparation made her experience significantly smoother than clients who arrive without any.

If you are reading this at night, sitting with your phone, wondering whether Mounjaro Malta — what to know before starting is the right thing to research before booking your first appointment — this is written for you. This is what to know before starting, in plain language, from someone who wants you to walk into that first appointment feeling informed and ready.

The medication does not do the thinking for you. But the thinking you do now is what makes the medication work.

Key Takeaways - Mounjaro (tirzepatide) is a weekly clinically supervised injection approved by the EMA for weight management - You must meet BMI or comorbidity criteria and have no contraindications before starting - Side effects are mostly gastrointestinal and peak in the first two weeks of each new dose - Protein targets and dietary quality matter significantly alongside the medication - A medically supervised programme includes monitoring, not just a prescription — results may vary for each individual

What Is Mounjaro and Why Is It Different?

Mounjaro is the brand name for tirzepatide, a weekly injection for weight management that the European Medicines Agency approved in November 2023. It is now available through medically supervised programmes in Malta. Understanding what makes it different from previous options is genuinely useful — not because you need to memorise the pharmacology, but because it helps you understand why so many people are seeing results that earlier medications could not consistently deliver. If you want a broader overview of how injectable weight loss options compare, our GLP-1 weight loss injections programme page explains the landscape in more detail.

Dual GIP and GLP-1 action explained

Tirzepatide is a dual receptor agonist. It activates two incretin hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). GLP-1 receptor agonists have been used in medicine for years — they mimic a hormone your intestine naturally releases after eating, which acts on the hypothalamus to reduce appetite suppression, slows gastric emptying so you feel full for longer, and helps regulate blood sugar. The addition of GIP activation appears to produce effects that go beyond what GLP-1 alone achieves, including direct actions on adipose tissue and the central nervous system. This dual mechanism is the structural reason that tirzepatide's clinical outcomes in trials have exceeded those of GLP-1-only medications in head-to-head comparisons.

How it compares to earlier weight loss injections

In the SURMOUNT-1 clinical trial (n=2,539 adults without type 2 diabetes, 72 weeks), participants on the 15mg tirzepatide dose achieved a mean body weight reduction of 20.9%, and 56.7% of those participants lost 20% or more of their body weight — a threshold no approved anti-obesity medicine had previously reached (Jastreboff AM et al., NEJM 2022). For context, the landmark STEP-1 trial of semaglutide 2.4mg (the active ingredient in Wegovy) showed a mean 14.9% body weight reduction at 68 weeks (Wilding JPH et al., NEJM 2021). The SURMOUNT-5 trial, published in 2024, directly compared tirzepatide against semaglutide 2.4mg and found tirzepatide produced approximately 47% greater weight loss. These are clinical trial figures under controlled conditions. Results may vary for each individual — but this context helps set realistic expectations.

Who Can Get Mounjaro in Malta?

BMI and health condition requirements

The EMA-approved indication for Mounjaro in chronic weight management covers adults with a BMI of 30 kg/m or above (obesity), or adults with a BMI of 27 kg/m or above (overweight) who have at least one weight-related comorbidity. Weight-related comorbidities in this context include type 2 diabetes, hypertension, dyslipidaemia (elevated cholesterol or triglycerides), obstructive sleep apnoea, or cardiovascular disease. At Carisma Slimming in Msida, Malta, the assessment process determines eligibility based on your full medical picture, not just your BMI figure alone.

It is also important to know that Mounjaro is indicated as an adjunct to a reduced-calorie diet and increased physical activity — not as a standalone treatment. That is not a caveat to gloss over. It is one of the most important things to understand before you start.

Contraindications you need to know about

There are specific medical situations where Mounjaro is not appropriate. These include a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2), current pregnancy or breastfeeding, severe gastrointestinal disease, and known hypersensitivity to tirzepatide. Your prescribing healthcare provider will review your full medical and family history at the consultation precisely to check for these. If any of these apply to you, it is important to disclose them fully — not to disqualify yourself, but so your doctor can recommend what is genuinely safe and appropriate for your situation. Prescribing should always be carried out by or in consultation with a healthcare professional with expertise in obesity management and insulin resistance.

How the Mounjaro Programme Works at a Malta Clinic

The consultation and assessment process

A medically supervised Mounjaro programme begins before the first injection. At Carisma Slimming in Malta, the initial consultation includes a review of your medical history, current medications, blood pressure, metabolic markers, and body composition. This is not a formality. It is the foundation that determines your starting dose, your titration schedule, and what monitoring you will need throughout. It is also where you and your doctor discuss your history with previous approaches, your lifestyle, and what realistic expectations look like specifically for you.

If you have questions — write them down and bring them. Your consultation is the right place to ask them, not after your first injection.

Dose escalation schedule: 2.5mg to 15mg

Mounjaro is started at 2.5mg weekly and increased in 2.5mg steps every four weeks, based on tolerability, up to a maximum dose of 15mg. This gradual escalation is not about being cautious for caution's sake — it is specifically designed to allow your body to adapt to the medication and minimise the gastrointestinal side effects that occur more frequently when higher doses are introduced too quickly. The therapeutic effect builds progressively: the most rapid weight loss phase typically occurs between weeks 4 and 16 as the dose escalates toward the effective range. The first four weeks at 2.5mg are primarily about tolerance and adaptation, so managing expectations during that period matters.

What ongoing monitoring looks like

In a medically supervised programme, the first consultation is not the only contact you have with your clinical team. Regular check-ins are built into the programme to track your progress, manage any side effects, review blood markers, and adjust the approach as needed. This ongoing relationship is what separates a medically supervised programme from obtaining a prescription through an unmonitored online service. The monitoring is not bureaucratic overhead — it is where problems get caught early and where the programme gets adjusted to your body's actual response.

What to Expect in the First Few Weeks

Common early side effects and how to manage them

The most commonly reported side effects of Mounjaro are gastrointestinal and are most likely to occur during the first four to eight weeks of each new dose. In the SURMOUNT-1 trial, nausea was reported in approximately 40 to 45% of participants at the highest dose, vomiting in approximately 25%, diarrhoea in 17 to 23%, and constipation in 20 to 24%. Fatigue was reported in around 13% of participants. These figures sound intimidating in a list. The clinical reality, for most people, is that symptoms are manageable, tend to peak within the first two weeks of each new dose, and subside as the body adapts.

Practical management strategies that consistently help include eating smaller meals and chewing slowly, avoiding high-fat, fried, or very spicy foods particularly in the early weeks, staying upright for 30 to 45 minutes after eating, drinking enough water throughout the day, and increasing dietary fibre gradually to manage constipation. Your clinical team will discuss these with you, but knowing them in advance means you are not caught off guard on day three.

When to contact your doctor

Most early side effects are expected and manageable. But there are situations where you should not wait for your next scheduled check-in. Contact your healthcare provider promptly if you experience severe persistent vomiting or diarrhoea that prevents you from keeping fluids down, significant abdominal pain (particularly if it is persistent and radiates to your back, which can be a sign of pancreatitis), yellowing of the skin or eyes, or any allergic reaction including difficulty breathing, swelling, or a rapid heartbeat. Your medically supervised team will give you clear guidance on this at your consultation, and you should have a direct point of contact throughout your programme.

What You Need to Change (Diet, Habits, Mindset)

Grace noticed something in her second month on Mounjaro that surprised her. The medication had done exactly what her doctor said it would: her appetite had reduced significantly, eating smaller portions felt natural for the first time in years, and the urgency she had always felt around food had quieted. But she also noticed that what she chose to eat with that reduced appetite still mattered enormously.

Why Mounjaro works best alongside dietary changes

Mounjaro reduces appetite suppression and slows gastric emptying, which means you will eat less. But eating less of the wrong things still produces poor outcomes. Ultra-processed foods, high-sugar, high-fat combinations, and heavily refined carbohydrates are known to activate hedonic eating pathways that can partially override the medication's appetite-suppressing signals. The Mediterranean dietary pattern is particularly well-suited to supporting Mounjaro outcomes — and for women in Malta, it is also culturally familiar. High vegetable and legume intake, olive oil, oily fish (sardines, tuna), wholegrains, and Greek yoghurt provide the nutritional quality that helps the medication do its best work.

Protein targets and eating rhythm

Protein deserves specific attention in any clinically supervised GLP-1 or tirzepatide programme. The recommended target is 1.2 to 1.6 grams of protein per kilogram of body weight per day, consistent with ESPEN guidelines for hypocaloric diets. For a woman weighing 90kg, that is approximately 108 to 144 grams of protein daily. This matters because tirzepatide creates a significant caloric reduction — typically 300 to 600 calories per day in practice. When total intake falls substantially, if protein is not actively prioritised, the body will catabolise lean muscle to meet protein needs. Studies of GLP-1-mediated weight loss indicate that lean mass loss can account for 25 to 40% of total weight lost when dietary protein is not optimised. Eating protein first at each meal, building meals around eggs, fish, legumes, Greek yoghurt, and lean poultry, and keeping protein-rich snacks available on days when nausea reduces your appetite — these habits compound the medication's effect rather than working against it.

Eating rhythm matters too. Three structured meals a day tends to work better than grazing, because it allows your body's natural satiety signals — which Mounjaro amplifies — to do their job fully between meals. For a full breakdown of how to structure your journey, our weight loss programme overview covers the approach we use across all phases.

Cost and Availability of Mounjaro in Malta

Mounjaro (tirzepatide) received EMA approval in November 2023 and is available through medically supervised programmes in Malta. Availability has expanded significantly since approval, though supply can vary by dose and pharmacy. At Carisma Slimming, our team manages prescription access and supply as part of your programme — you are not navigating pharmacy availability alone.

The cost of Mounjaro in Malta includes both the medication and the clinical oversight. Monthly costs vary depending on your dose, the duration of your programme, and the package you choose. A full breakdown of current pricing is discussed at your initial consultation. What is worth understanding in advance is that the total investment in a medically supervised programme reflects not just the medication but the monitoring, the clinical expertise, the nutritional guidance, and the ongoing support that separates a safe, effective programme from an unsupervised prescription.

If you are comparing costs, compare whole programmes rather than medication cost alone. A prescription without monitoring is not the same thing as a medically supervised Mounjaro programme in Malta.

Questions to Ask Your Doctor at the First Appointment

Coming prepared with questions is one of the most useful things you can do. Here are the questions worth having answered before your first dose:

About your eligibility: "Based on my medical history and current medications, am I a good candidate for tirzepatide? Are there any specific risks for me personally?"

About the dose and schedule: "What dose will I start on, and what is the expected escalation schedule based on my situation?"

About side effects: "What should I do if the nausea is severe in the first week? What is the threshold for contacting you versus managing it at home?"

About monitoring: "What blood tests or health checks will I need during the programme, and how often will we review my progress?"

About diet: "What should my protein target be at my current weight? Do you have a dietary guide I can follow alongside the medication?"

About stopping: "What is the long-term plan? If I reach my goal weight, how do we approach stopping the medication safely?"

About what success looks like: "What would you expect for someone with my profile over the first 12 weeks?"

A doctor in a medically supervised programme should welcome every one of these questions. If a provider discourages you from asking, that is useful information too.

FAQs About Mounjaro in Malta

Is Mounjaro available in Malta right now?

Yes. Mounjaro (tirzepatide) received EMA approval for chronic weight management in November 2023 and is available through medically supervised programmes in Malta. Availability by dose can vary — higher doses were slower to reach full supply post-approval, and occasional short-term shortfalls at specific pharmacies occur. At Carisma Slimming, we manage prescription access and supply coordination as part of your programme so that interruptions are minimised. The best way to confirm current availability and your specific dose is at your initial consultation.

How much does Mounjaro cost in Malta per month?

The monthly cost of a Mounjaro programme in Malta depends on your prescribed dose, the duration of your programme, and the level of clinical support included. Dose escalation means cost typically rises over the first five months as you move from 2.5mg toward your target dose. We discuss full, transparent pricing at your free initial consultation at Carisma Slimming. When budgeting, it is worth factoring in that a complete medically supervised programme includes clinical oversight, monitoring, and support — not just the medication itself. Results may vary for each individual, but the structure of professional supervision is what protects your investment.

What are the most common Mounjaro side effects I should prepare for?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. In the SURMOUNT-1 trial, nausea was reported in approximately 40 to 45% of participants at the highest dose, typically peaking in the first two to four weeks of each new dose step before subsiding. Fatigue during the initial weeks is also common. The slow titration schedule — starting at 2.5mg and increasing every four weeks — is specifically designed to reduce the severity of these effects. Most people find the first two weeks of each new dose the most challenging, with significant improvement as the body adapts. Your clinical team will give you specific strategies for managing symptoms before they begin.

Do I need to follow a specific diet on Mounjaro?

No specific diet is mandatory, but your dietary choices significantly affect how well the medication works and how much of the weight you lose is fat rather than muscle. Protein intake is the most important nutritional variable — the recommended target is 1.2 to 1.6g per kilogram of body weight per day during active tirzepatide-assisted weight loss, consistent with ESPEN guidelines. A Mediterranean-style eating pattern that is high in vegetables, legumes, lean protein, and wholegrains tends to produce the best outcomes. Ultra-processed foods and high-sugar combinations can partially override the medication's appetite-suppression. Your medically supervised programme at Carisma Slimming includes dietary guidance built around what is practical for your life.

How long will I need to stay on Mounjaro?

This varies by individual and is something to discuss with your doctor based on your goals, health history, and response to the medication. Clinical trial data suggests that most of the weight loss effect occurs in the first 36 to 72 weeks. The important thing to understand about duration is what happens when the medication stops. SURMOUNT-4 data shows that participants who discontinued tirzepatide after achieving significant weight loss regained approximately 56% of the lost weight within 52 weeks of stopping. This is not a failure of willpower — it is the body's homeostatic systems reasserting themselves once the medication's appetite signals cease. Maintenance planning is a conversation to have with your doctor from the beginning, not after you decide to stop.

What happens if I miss a Mounjaro injection?

If you miss an injection and your next scheduled dose is more than four days away, you can take the missed dose as soon as you remember. If your next dose is fewer than four days away, skip the missed dose and take your next one as scheduled. Do not take a double dose to compensate. A single missed injection is unlikely to significantly affect your progress, but missed doses across several weeks may slow your titration progress. Your medically supervised team at Carisma Slimming will guide you on exactly how to handle this in your situation, particularly during dose escalation phases.

Is Mounjaro safe long-term?

Tirzepatide was studied over 72 weeks in the SURMOUNT programme trials, which represents the most robust long-term safety data currently available. The EMA approval for chronic weight management is based on this data. The most serious potential risks — acute pancreatitis and gallbladder disease — are rare: cholelithiasis (gallstones) was observed in approximately 1.1% of tirzepatide participants versus 0.4% in the placebo group in SURMOUNT-1. The SURMOUNT-4 extension data further confirms the safety profile over longer durations. Individuals with a personal or family history of medullary thyroid carcinoma or MEN2 should not take tirzepatide. Long-term post-marketing surveillance is ongoing, as with all relatively recently approved medicines. A medically supervised programme ensures that any emerging signals are monitored and responded to in the context of your individual health profile.

You Deserve to Start Informed, Not Afraid

Grace came back to our clinic for her four-week check-in with notes. Her nausea had been noticeable in week two at the 2.5mg dose, manageable in week three, and gone by week four. She had climbed the stairs at her office building one morning without stopping to catch her breath at the top — and stood there for a moment, surprised. She had not noticed, until that moment, that she had been pausing at every landing for the past two years.

That is what the early part of this journey looks like, often. Not dramatic. Not a transformation photo. Just a morning where something that had become ordinary effort quietly becomes easy again.

If you are considering Mounjaro in Malta and you want to understand whether it is right for you — not whether it is available, not whether other people have tried it, but whether it makes sense for your body, your health, your life — that is exactly what a free slimming consultation at Carisma Slimming is for. You will meet a doctor. You will ask your questions. You will leave knowing, not wondering.

You deserve support that is built around your situation, not a generic protocol applied to everyone. You deserve honest answers about what to expect, what to prepare for, and what realistic progress looks like over the months ahead. And you deserve to start this knowing that the team around you is not going anywhere.

Eight weeks from now, the decision you make this week could be the one you look back on as the one that finally felt different.

Book your free consultation at Carisma Slimming in Malta today. We will take it from there, one step at a time.

With you every step, Katya

This article is for informational purposes only and does not constitute medical advice. Mounjaro (tirzepatide) is a prescription medication that must be prescribed and supervised by a qualified healthcare professional. Individual results may vary. Always consult your doctor before starting any new medication or weight management programme.

Sources: Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. NEJM 2022;387:205-216 (SURMOUNT-1). Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. NEJM 2021;384:989-1002 (STEP-1). European Medicines Agency. Mounjaro: EPAR summary. EMA/725761/2023. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet 2023;402(10402):613-626. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA 2024;331(1):38-48.

FAQ Schema (Structured Data)

Q: Is Mounjaro available in Malta right now? A: Yes. Mounjaro (tirzepatide) received EMA approval for chronic weight management in November 2023 and is available through medically supervised programmes in Malta. Availability by dose can vary — higher doses were slower to reach full supply post-approval, and occasional short-term shortfalls at specific pharmacies occur. At Carisma Slimming, we manage prescription access and supply coordination as part of your programme so that interruptions are minimised. The best way to confirm current availability and your specific dose is at your initial consultation.

Q: How much does Mounjaro cost in Malta per month? A: The monthly cost of a Mounjaro programme in Malta depends on your prescribed dose, the duration of your programme, and the level of clinical support included. Dose escalation means cost typically rises over the first five months as you move from 2.5mg toward your target dose. We discuss full, transparent pricing at your free initial consultation at Carisma Slimming. When budgeting, it is worth factoring in that a complete medically supervised programme includes clinical oversight, monitoring, and support — not just the medication itself. Results may vary for each individual.

Q: What are the most common Mounjaro side effects I should prepare for? A: The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. In the SURMOUNT-1 trial, nausea was reported in approximately 40 to 45% of participants at the highest dose, typically peaking in the first two to four weeks of each new dose step before subsiding. Fatigue during the initial weeks is also common. The slow titration schedule — starting at 2.5mg and increasing every four weeks — is specifically designed to reduce the severity of these effects. Most people find the first two weeks of each new dose the most challenging, with significant improvement as the body adapts.

Q: Do I need to follow a specific diet on Mounjaro? A: No specific diet is mandatory, but your dietary choices significantly affect how well the medication works and how much of the weight you lose is fat rather than muscle. Protein intake is the most important nutritional variable — the recommended target is 1.2 to 1.6g per kilogram of body weight per day during active tirzepatide-assisted weight loss, consistent with ESPEN guidelines. A Mediterranean-style eating pattern tends to produce the best outcomes. Ultra-processed foods and high-sugar combinations can partially override the medication's appetite-suppression. Your medically supervised programme at Carisma Slimming includes dietary guidance built around what is practical for your life.

Q: How long will I need to stay on Mounjaro? A: This varies by individual and is something to discuss with your doctor based on your goals, health history, and response to the medication. Clinical trial data suggests that most of the weight loss effect occurs in the first 36 to 72 weeks. SURMOUNT-4 data shows that participants who discontinued tirzepatide after achieving significant weight loss regained approximately 56% of the lost weight within 52 weeks of stopping. This is not a failure of willpower — it is the body's homeostatic systems reasserting themselves once the medication's appetite signals cease. Maintenance planning is a conversation to have with your doctor from the beginning, not after you decide to stop.

Q: What happens if I miss a Mounjaro injection? A: If you miss an injection and your next scheduled dose is more than four days away, you can take the missed dose as soon as you remember. If your next dose is fewer than four days away, skip the missed dose and take your next one as scheduled. Do not take a double dose to compensate. A single missed injection is unlikely to significantly affect your progress, but missed doses across several weeks may slow your titration progress. Your medically supervised team at Carisma Slimming will guide you on exactly how to handle this in your situation, particularly during dose escalation phases.

Q: Is Mounjaro safe long-term? A: Tirzepatide was studied over 72 weeks in the SURMOUNT programme trials, which represents the most robust long-term safety data currently available. The EMA approval for chronic weight management is based on this data. The most serious potential risks — acute pancreatitis and gallbladder disease — are rare: cholelithiasis was observed in approximately 1.1% of tirzepatide participants versus 0.4% in the placebo group in SURMOUNT-1. SURMOUNT-4 extension data further confirms the safety profile over longer durations. A medically supervised programme ensures any emerging signals are monitored and responded to in the context of your individual health profile.

Internal Links Placed

free slimming consultation at Carisma Slimming • free consultation (CTA section) • GLP-1 weight loss injections programme • weight loss programme overview

CTA

If you are considering Mounjaro in Malta and you want to understand whether it is right for you — not whether it is available, not whether other people have tried it, but whether it makes sense for your body, your health, your life — that is exactly what a free slimming consultation at Carisma Slimming is for. You will meet a doctor. You will ask your questions. You will leave knowing, not wondering. Eight weeks from now, the decision you make this week could be the one you look back on as the one that finally felt different. Book your free consultation at Carisma Slimming in Malta today. With you every step, Katya.

Image Credits

Hero Image URL: https://images.pexels.com/photos/7579831/pexels-photo-7579831.jpeg?auto=compress&cs=tinysrgb&dpr=2&h=650&w=940 • Photographer: cottonbro studio • Pexels Page: https://www.pexels.com/photo/a-doctor-talking-the-patient-7579831/ • Alt text: Doctor and patient consultation in Malta clinic — Mounjaro Malta what to know before starting • Caption: Starting Mounjaro in Malta begins with an informed conversation with your doctor. • Filename: mounjaro-malta-doctor-consultation.jpg • Query used: doctor patient consultation woman warm clinic

Inline Image URL: https://images.pexels.com/photos/15319047/pexels-photo-15319047.jpeg?auto=compress&cs=tinysrgb&dpr=2&h=650&w=940 • Photographer: beyzahzah • Alt text: Female nutritionist in office surrounded by fresh fruits and vegetables, holding broccoli • Query used: nutritionist wellness office healthy food

QC Report

Score: 84/100 | Status: ⚠️ FLAGGED FOR REVIEW

✅ validationOpening • ❌ primaryKeywordInH1 • ✅ minimumWordCount1700 • ✅ resultsVaryPresent • ✅ medicallySupervisedPresent • ✅ minimum5FAQs • ❌ minimum2InternalLinks • ✅ consultationLinkPresent • ✅ fearFAQPresent • ✅ zeroShameLanguage • ✅ nonScaleWinsPresent • ✅ minimum2CredibleSources • ✅ maltaMentioned • ✅ ymylSafe

Issues CRITERION 7 FAIL — minimum2InternalLinks: The /glp1 internal link ('GLP-1 Medical Weight Loss Programme') is declared in metadata but does NOT appear embedded in the article body. Only one internal link (/consultation) is present in the prose. A second internal link must be woven into the article text — recommended placement: in the 'What Is Mounjaro and Why Is It Different?' section or the 'How the Mounjaro Programme Works at a Malta Clinic' section, with anchor text referencing the GLP-1 programme page. • CRITERION 2 FAIL — primaryKeywordInH1: The H1 reads 'Mounjaro in Malta: Everything You Should Know Before Starting'. The declared primary keyword is 'Mounjaro Malta what to know before starting'. The phrase 'what to know' does not appear in the H1 — it is replaced by 'Everything You Should Know'. Recommend revising H1 to 'Mounjaro Malta: What to Know Before Starting' (52 characters, exact keyword match, clean and natural).

Improvements The SURMOUNT-5 '47% greater weight loss' claim is attributed to a 2024 trial by name in the text but does not appear in the formal sources list at the bottom — add the full citation to maintain E-E-A-T consistency and YMYL credibility. • The /glp1 internal link anchor 'GLP-1 Medical Weight Loss Programme' is strong commercial anchor text — when embedded in the body, place it at a point of natural contextual relevance (e.g., when comparing tirzepatide to GLP-1-only medications) rather than as a standalone sentence. • The FAQ section has 7 questions with comprehensive answers, but the 'Is Mounjaro safe long-term?' answer could reference SURMOUNT-4 explicitly (already cited in the body FAQ section) to strengthen the schema answer's standalone credibility for featured snippet extraction. • Consider adding a specific area mention within Malta (e.g., clinic location) in at least one body paragraph to strengthen hyperlocal SEO signals beyond the island-level 'Malta' references. • No meta title or meta description was provided for review — these should be supplied with the next submission for full SEO dimension scoring per the QC framework.

SEO Notes Primary keyword 'Mounjaro Malta what to know before starting' appears in the intro within the first 150 words ('wondering whether Mounjaro Malta might finally be the thing') and across multiple H2 headings including 'Who Can Get Mounjaro in Malta?', 'Cost and Availability of Mounjaro in Malta', and 'FAQs About Mounjaro in Malta'. Keyword density for 'Mounjaro' across 2,180 words is estimated at approximately 1.4-1.8% — slightly elevated but defensible given it is the subject of the article. LSI terms are strong: tirzepatide, GIP, GLP-1, incretin, SURMOUNT, EMA, BMI, titration, dose escalation, gastrointestinal, pancreatitis, cholelithiasis, ESPEN, Mediterranean diet — all present naturally. The 7-question FAQ schema with structured answers of appropriate length is well-optimised for People Also Ask extraction. No meta title or description was submitted for character-count audit. The H1 fix (criterion 2) is the only SEO-impacting structural change required alongside the internal link fix (criterion 7).

E-E-A-T Assessment Exceptionally strong. The post demonstrates genuine clinical expertise through specific trial citations (SURMOUNT-1 n=2,539, STEP-1 semaglutide comparison, SURMOUNT-4 rebound data), named publication venues (NEJM, Lancet), EMA approval details with date and reference number, ESPEN protein guidelines with specific g/kg targets, and mechanistic explanation of dual GIP/GLP-1 action that goes well beyond surface-level description. Malta-specific context is woven throughout, not appended. The Grace persona grounds clinical information in a recognisable human experience for the target reader. The medical disclaimer, contraindication list, and 'results may vary' disclosures meet YMYL standards. Trust signals are high: no over-promising, weight regain risk disclosed proactively, prescriber requirement stated explicitly. This post would pass a Google Quality Rater assessment for expertise and trustworthiness in the medical/health YMYL category.